Affymetrix has received clearance under the FDA's de novo program to market its CytoScan Dx test. The blood-based assay, designed to identify chromosomal changes that could be linked to intellectual disability or developmental delay in children, can help clinicians and parents provide proper support and care, an FDA official said.

Related Summaries